Fabry disease screening in kidney transplant patients: A single-center study in Türkiye
Gulhane Medical Journal, cilt.64, sa.4, ss.315-319, 2022 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 64 Sayı: 4
- Basım Tarihi: 2022
- Doi Numarası: 10.4274/gulhane.galenos.2022.27870
- Dergi Adı: Gulhane Medical Journal
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, CAB Abstracts, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.315-319
- Anahtar Kelimeler: Fabry disease, Kidney transplant patients, Screening
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aims: This study aimed to screen for Fabry disease in adult kidney transplant patients at a nephrology clinic in Türkiye. Methods: This cross-sectional, single-center study prospectively enrolled kidney transplant recipients regardless of the etiology of renal failure. α-galactosidase A (α-GLA) enzyme activity and α-GLA gene analysis were used to screen for Fabry disease. The screening was initiated by measuring enzyme activity in males, and those with <2.5 nmol/mL/hour activity underwent gene analysis. Females were screened directly by gene analysis, independent of the enzyme activity. Results: We screened 125 patients (age: 48.9±10.1, male: 70.4%). Gene analysis was performed on a 68-year-old male patient with enzyme activity at the lower end of the reference range. No mutations associated with Fabry disease were detected. The enzyme activity test was considered false positive. A heterozygous c.937G>T (p. D313Y) mutation was detected in the gene analysis of a 29-year-old female patient. However, systemic evaluation did not reveal any clinical findings consistent with Fabry disease. Screening tests were within normal limits in other patients. Although there were abnormal screening findings in 2 patients, none was diagnosed with Fabry disease. Conclusions: Screening studies for Fabry disease in kidney transplant patients may contribute to the determination of the true prevalence.